Medical and Pharmaceutical Australian biotech uncovers broader view of tumour genetics with liquid biopsy The team developed the study in collaboration with US sequencing company Illumina Joseph Morton7 hours ago
Medical and Pharmaceutical Lung cancer screening truck heads for remote mining towns in Western Australia It is the first in the state to offer low-dose CT scans in isolated communities Rowan Dunne2 days ago
AI and Autonomy Qure.ai offers artificial intelligence training in US to transform clinical operations The initiative helps to advance AI adoption while supporting ongoing learning for radiologic professionals across the country Joseph Morton4 days ago
Health & Wellness Quest Diagnostics and University of Texas want to promote more cancer screenings Quest plans to refine, expand, and validate the MCaST technology for its own lab-developed test Joseph Morton6 days ago
Medical and Pharmaceutical Breath Diagnostics opens Respiratory Innovation Summit with captivating presentation It was an honour for the company to be selected to kick off this prestigious event Rowan DunneJune 9, 2025
Medical and Pharmaceutical Dying woman blames CT scan technicians for cancer spread, files lawsuit Their failure to properly interpret the results will cost her life, she claims Rowan DunneJune 6, 2025
Medical and Pharmaceutical Combining mammograms with lung cancer screening can boost female uptake A recent study from Stanford Medicine made this conclusion Rowan DunneJune 4, 2025
Medical and Pharmaceutical Australia’s first national lung cancer screening program begins in July The aim of the game is to save 12,000 lives by 2035 Rowan DunneJune 3, 2025
Medical and Pharmaceutical Against the rise of early onset cancer: a Mugglehead roundup Cancer treatment markets are set to expand rapidly over the next decade Joseph MortonMay 29, 2025
Medical and Pharmaceutical Lucid Diagnostics joins Russell 2000 and 3000 indexes Investment managers and institutional investors widely use the Russell indexes for both index funds and active investment benchmarks Joseph MortonMay 27, 2025